A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

Recruiting

Phase 2

NORA520A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

Sponsor:

DuKang Pharmaceuticals, Inc.

Code:

NCT06285916

Conditions

Depression, Postpartum

Postpartum Depression

Post-partum Depression

Postnatal Depression

Post-Natal Depression

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Not accepted

Interventions

NORA520 Dose 1

NORA520 Dose 2

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by DuKang Pharmaceuticals, Inc. on 2025-05-01.